Biovica’s annual report for the fiscal year 2019/2020 is published on our website https://biovica.com/investor-relations/financials/ Contact Anders Rylander, CEOPhone: +46-18-444 48 35E-mail: email@example.com Cecilia Driving, EVP CFO/HR/IRPhone +46-73-125 92 47E-mail: firstname.lastname@example.org Biovica – Treatment decisions with greater confidence Biovica develops and commercializes blood-based biomarker assays to evaluate efficacy of cancer treatments. Biovica’s assay DiviTum® measure cell proliferation […]
Biovica, active in cancer diagnostics, today announced that the analytical validation of the blood test DiviTum has been completed. The validation aims to verify technical and precision requirements defined in consultation with the US Food and Drug Administration (FDA). The analytical validation is an important part of the application for US market approval.
Preparations for the launch of DiviTum® have started
Uppsala, Sweden, May 22, 2020. The ASCO educational book 2020 highlights DiviTum® as a solution to address unmet needs within monitoring treatment effect of CDK4/6 inhibitors.
Uppsala, Sweden, May 11, 2020. The scientific journals British Journal of Cancer, a Nature journal, and Biomarkers in Medicine have published articles on DiviTum® results and TK activity as a biomarker for evaluating efficacy of CDK4/6 inhibitors. The editorials conclude that DiviTum data has the potential to become a standard prognostic biomarker and tool for early recognition of treatment resistance in metastatic breast cancer.
Uppsala, Sweden, May 11, 2020. Biovica, active in cancer diagnostics, hosts today its virtual capital market day at 14.00-16.00. The purpose is to provide an update on Biovica’s market launch strategy and goals. Biovica is also providing a market share target three years after launch of DiviTum®.
Biovica, active in cancer diagnostics, will host a virtual Capital Markets Day on Monday 11 May from 14:00 to 16:00.
Biovica, active in cancer diagnostics, will host a virtual Capital Markets Day on Monday 11 May from 14.00 to 16:00.
Biovica initiates a collaboration with Mayo Clinic to study DiviTum® for the on-treatment monitoring of metastatic breast cancer patients receiving CDK 4/6 inhibitors
Biovica and Mayo Clinic have entered into an agreement to study the clinical benefit of using DiviTum® as a blood-based test, monitoring the tumor response to therapy in patients with metastatic breast cancer.
Uppsala, Sweden, March 25, 2020. Biovica, active in cancer diagnostics, today announced that Robert Dann is joining the organization as SVP Marketing and US Business and will be part of the management team. The appointment marks a significant milestone in the upcoming commercialization of DiviTum® on the US market.